Vadadustat Hits Non-Inferiority Endpoint in VOCAL, Backing Three-Times-Weekly Dosing
AKBA sits 28% above its 52-week low of $0.542.
Summary
Akebia's VOCAL trial met its primary endpoint: three-times-weekly vadadustat was non-inferior to ESA (Mircera) in maintaining hemoglobin in 353 in-center hemodialysis patients. The least squares mean Hb difference was -0.45 g/dL with a 95% CI of -0.71 to -0.19, clearing the -0.75 g/dL non-inferiority margin, and treatment-emergent serious adverse event rates were similar (159.7 vs 183.9 events per 100 patient-years). This follows the October 26 presentation of VOICE data showing a hospitalization-driven safety benefit versus Epogen, building a comparative dataset against multiple ESAs. The commercial relevance is dosing convenience: Vafseo is currently approved and marketed as once-daily, and a TIW regimen could fit in-center dialysis workflows, though it remains investigational and would require an FDA label expansion. The company is small and posted a 3Q loss of $14.4 million with Auryxia facing generic erosion, so Vafseo label expansion is the main growth lever; note the October 23 Nasdaq notice that shares closed below $1.00 for 30 consecutive business days, with until April to regain compliance.
At the time of this announcement, AKBA was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.5M. The 52-week trading range was $0.54 to $2.15. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.